New injection tested for Tough-to-Treat Muscle-Weakening disease
NCT ID NCT06965309
Summary
This early study tested a new injection called HN2301 in a small group of adults with myasthenia gravis that did not respond well to standard treatments. The main goal was to check if the treatment was safe and tolerable. Researchers also looked for early signs that it might help improve patients' symptoms and daily function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital (Songjiang Branch) of Shanghai Jiao Tong University School of Medicine
Shanghai, 201600, China
Conditions
Explore the condition pages connected to this study.